BioCentury
ARTICLE | Emerging Company Profile

GentiBio: combining trio of platforms to enhance Treg therapies

Launches with $20M to engineer stable, tunable and tissue-specific Treg cell therapies

August 11, 2020 11:00 PM UTC

GentiBio launched this summer with a suite of technologies to develop next-generation Treg cell therapies that overcome several of the modality’s historical shortcomings, including stability and specificity. The company, which is focused on autoimmune, alloimmune and allergic diseases, raised $20 million in seed funding last week from OrbiMed Advisors, Novartis Venture Fund and RA Capital Management.

Regulatory T cells (Tregs) suppress immune responses and counter the immune overactivation that characterizes autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. ...

BCIQ Target Profiles

Forkhead box P3 (FOXP3)